000095352 001__ 95352
000095352 005__ 20210902121824.0
000095352 0247_ $$2doi$$a10.3390/jcm9061632
000095352 0248_ $$2sideral$$a119054
000095352 037__ $$aART-2020-119054
000095352 041__ $$aeng
000095352 100__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Yolanda$$uUniversidad de Zaragoza
000095352 245__ $$aPrevalence and Comorbidity of Atopic Dermatitis in Children: A Large-Scale Population Study Based on Real-World Data
000095352 260__ $$c2020
000095352 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095352 5203_ $$aThis study aimed at exploring atopic dermatitis (AD) prevalence in children and exhaustively analyzing their comorbidity. We conducted a descriptive analysis of their socio-demographic and comorbidity characteristics in the EpiChron Cohort (Aragon, Spain). Adjusted odds ratios (OR) were calculated for each comorbidity using logistic regression models. In total, 33, 591 children had a diagnosis of AD, resulting in an overall prevalence of 15.5%. AD prevalence was higher in girls compared to boys, in 3-9-year-olds compared to children of other ages, and in Spanish children compared to those of other nationalities. Multimorbidity was present in 43% of children, with the most frequent chronic comorbidities being asthma (13.1%), psychosocial disorders (7.9%), and visual impairment (7.8%). Many diseases were, regardless of their prevalence, statistically associated with AD. The strongest associations (odds ratio (OR) (95% confidence interval (CI))) were found in asthma (2.10 (2.02-2.17)), allergic rhinitis (2.00 (1.91-2.10)), and irritable bowel syndrome (1.90 (1.56-2.31)). A better understanding of the array of comorbidities associated with AD in children might help improve their clinical management. Future longitudinal studies are encouraged to shed light on the potential underlying pathophysiological mechanisms involved in the identified associations.
000095352 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B18-17D$$9info:eu-repo/grantAgreement/ES/DGA-FEDER/B01-20R
000095352 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095352 590__ $$a4.241$$b2020
000095352 591__ $$aMEDICINE, GENERAL & INTERNAL$$b39 / 169 = 0.231$$c2020$$dQ1$$eT1
000095352 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095352 700__ $$aPerez-Gilaberte, Juan Blas
000095352 700__ $$aPoblador-Plou, Beatriz
000095352 700__ $$aBliek-Bueno, Kevin
000095352 700__ $$0(orcid)0000-0002-5440-1710$$aGimeno-Miguel, Antonio
000095352 700__ $$aPrados-Torres, Alexandra
000095352 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000095352 773__ $$g9, 6 (2020), 1632 [12 pp.]$$pJ. clin.med.$$tJOURNAL OF CLINICAL MEDICINE$$x2077-0383
000095352 8564_ $$s275839$$uhttps://zaguan.unizar.es/record/95352/files/texto_completo.pdf$$yVersión publicada
000095352 8564_ $$s466680$$uhttps://zaguan.unizar.es/record/95352/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095352 909CO $$ooai:zaguan.unizar.es:95352$$particulos$$pdriver
000095352 951__ $$a2021-09-02-10:10:44
000095352 980__ $$aARTICLE